Activin and Inhibin

GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT) , which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control,

GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT) , which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control,

Gossypetin is a hexahydroxylated flavonoid and is a potent mitogen-activated protein kinase kinase (MKK)3 and MKK6 inhibitor with strongly attenuates the MKK3/6-p38 signaling pathway, has various pharmacological activities, including antioxidant,

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.In VivoLow-dose GP531 reduces infarct size by 34% compared with vehicle

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.In VivoLow-dose GP531 reduces infarct size by 34% compared with vehicle

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.In VivoLow-dose GP531 reduces infarct size by 34% compared with vehicle

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.In VivoLow-dose GP531 reduces infarct size by 34% compared with vehicle

GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.In VitroGPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with

GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.In VitroGPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with

GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.In VitroGPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with

GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.In VitroGPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with

GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209.In VitroGPR120 Agonist 2 is a GPR120 agonist which is useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with